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AbstrACt
Objective To assess pathways and associated costs of 
seeking care from the onset of symptoms to diagnosis 
in patients with confirmed and presumptive tuberculosis 
(TB).
Design Cross-sectional study.
setting District hospital in Dar es Salaam, Tanzania.
Participants Bacteriologically confirmed TB and 
presumptive TB patients.
Primary and secondary outcome measures We 
calculated distance in metres and visualised pathways 
to healthcare up to five visits for the current episode of 
sickness. Costs were described by medians and IQRs, with 
comparisons by gender and poverty status.
results Of 100 confirmed and 100 presumptive TB 
patients, 44% of confirmed patients sought care first 
at pharmacies after the onset of symptoms, and 42% 
of presumptive patients did so at hospitals. The median 
visits made by confirmed patients was 2 (range 1–5) and 
2 (range 1–3) by presumptive patients. Patients spent 
a median of 31% of their monthly household income 
on health expenditures for all visits. The median total 
direct costs were higher in confirmed compared with 
presumptive patients (USD 27.4 [IQR 18.7–48.4] vs USD 
19.8 [IQR 13.8–34.0], p=0.02), as were the indirect 
costs (USD 66.9 [IQR 35.5–150.0] vs USD 46.8 [IQR 
20.1–115.3], p<0.001). The indirect costs were higher in 
men compared with women (USD 64.6 [IQR 31.8–159.1] 
vs USD 55.6 [IQR 25.1–141.1], p<0.001). The median total 
distance from patients’ household to healthcare facilities 
for patients with confirmed and presumptive TB was 
2338 m (IQR 1373–4122) and 2009 m (IQR 986–2976) 
respectively.
Conclusions Patients with confirmed TB have 
complex pathways and higher costs of care compared 
with patients with presumptive TB, but the costs 
of the latter are also substantial. Improving access 
to healthcare and ensuring integration of different 
healthcare providers including private, public health 
practitioners and patients themselves could help in 
reducing the complex pathways during healthcare 
seeking and optimal healthcare utilisation.
bACkgrOunD 
Patients with confirmed and presumptive 
tuberculosis (TB) follow complex pathways 
to healthcare. Pathways to healthcare are the 
steps/ways the confirmed and presumptive 
patients take from the initial point of seeking 
healthcare to the point of diagnosis and treat-
ment.1 2 Many patients consult various health-
care providers before being diagnosed with 
TB.3 4 These pathways are usually complex 
and delayed diagnosis and treatment may 
increase morbidity and mortality.5 The WHO 
estimated an incidence of 10.4 million TB 
cases in 2016, yet only 6.3 million new TB 
cases were notified to national authorities 
and reported to WHO.6 Although many 
factors contribute to this notification short-
fall, the complexity of pathways to TB care 
may substantially contribute to low notifica-
tion rates.
TB is widely regarded as a disease of poverty 
due to its disproportionate effects on the 
marginalised populations.7 8 To help socially 
and economically marginalised groups fight 
the disease, healthcare facilities diagnose 
and treat TB free of charge in countries with 
a high TB burden.9 However, patients with 
symptoms of TB face high direct and indirect 
strengths and limitations of this study
 ► We present data on pathways to care and assess 
costs of care in patients with confirmed and pre-
sumptive tuberculosis (TB) in Tanzania.
 ► We estimate costs of care by stratifying costs ac-
cording to poverty status and gender.
 ► Estimated costs for TB diagnosis did not account for 
HIV and other comorbidities.
 ► The accuracy of reported costs may have been com-
promised by recall bias.
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costs for diagnosis and treatment,10–13 and these costs 
are usually higher for patients with confirmed TB than 
presumptive cases.3 14
Prior to diagnosis, the pathways to care of presump-
tive TB in Tanzania are complex. They usually involve 
consultations with more than one healthcare provider 
with suboptimal or no means for diagnosing TB.4 15 
The complex pathways to care may begin at pharmacies 
and basic healthcare facilities with no TB diagnostics 
before reaching healthcare facilities with TB diagnostic 
capacity.14
A national TB prevalence survey in Tanzania indicated 
that the case detection rate of TB was below 50%.16 This 
result may be due to the complexity and the high cost 
of care.15 17 18 The recommended pathway to care for 
patients with TB is to present themselves to the appro-
priate healthcare facilities for TB diagnosis after recogni-
tion of TB symptoms.9 19 20
Research has focused predominantly on patients who 
have already been diagnosed within the healthcare system, 
rather than costs for presumptive TB cases prior to diag-
nosis.21 Costs for presumptive cases are not well under-
stood, especially in sub-Saharan Africa.3 22 In addition to 
financial costs, sociocultural and gender-related factors 
can shape how patients seek healthcare,23 yet such studies 
of the influence of these factors are scarce.24 Finally, only 
few studies have examined pathways and costs of seeking 
healthcare by comparing confirmed and presumptive TB 
patients.3 10 25
Objective
We aimed to assess the pathways to care and associated 
costs of seeking care from the onset of symptoms until TB 
diagnosis in patients with confirmed and presumptive TB 
in Dar es Salaam, Tanzania.
MethODs
study setting and study population
The study was conducted within the framework of an 
on-going TB cohort (TB-DAR) study among the adult 
population in the Temeke district of Dar es Salaam, 
Tanzania.4 The district is densely populated with a popu-
lation of 1 369 000 persons.26 It ranks as the poorest in 
the region with 29% of the households living below the 
poverty line, resulting in 295 poor persons per square kilo-
metre.27 The number of healthcare facilities in Temeke 
district is low compared with other districts in the region. 
There are six public and private hospitals, eight health 
centres and 121 dispensaries.28 In 2011, a total of 4112 TB 
cases of all forms were notified in the Temeke district, of 
which 1760 (43%) were smear positive.29
We included adult, sputum smear-positive patients with 
TB and presumptive TB cases who were consecutively 
enrolled in the TB-DAR study4 30 between August 2016 
and January 2017, until the target sample size of 100 
patients in each category was reached (figure 1). Based 
on power calculation and previous studies,3 25 we included 
100 patients with confirmed TB and 100 patients with 
presumptive TB allowing to detect a statistically significant 
difference in the prevalence of diagnostic delay between 
the two groups of patients with a power of 80% in case of 
a true difference of at least 20%. Inclusion criteria were, 
(i) ≥18 years of age at recruitment; (ii) bacteriologically 
confirmed TB diagnosis, or with presumptive TB and 
(iii) residency in the Wailes I or II subdistricts of Temeke. 
Additionally, patients in both groups were screened for 
TB using sputum smear microscopy and Xpert MTB/RIF. 
We excluded patients who did not provide consent and 
those with incomplete data.
Data collection
Interviews
We interviewed patients, reconstructed retrospectively 
visits to healthcare facilities and collected data on direct 
and indirect costs using a standardised questionnaire 
at the TB clinic. The data collected included patient 
sociodemographic and socioeconomic characteristics, 
TB symptoms, the duration of the time from the onset 
of symptoms until the first help seeking in a health-
care facility and the number of healthcare facilities that 
patients with confirmed and presumptive TB had visited. 
Data were recorded on tablets using the OpenDataKit 
application.31
Pathways to care
Visualisation charts were used to reconstruct the pathways 
to care for each patient from the onset of symptoms until 
TB diagnosis up to five visits. We assessed all visits to the 
healthcare facilities made, including transport used and 
approximate distance from the household to the respec-
tive healthcare facilities. Healthcare facilities included 
pharmacies, dispensaries, health centres, traditional and 
religious healers and private and government hospitals.
Geographical information system data
We collected geo-coordinates of healthcare facilities, 
including all pharmacies, dispensaries, private and 
governmental hospitals, health centres as well as tradi-
tional healers identified in the study area. We also 
collected geo-coordinates of households of all patients 
who participated in the study.
Costs of care
We asked patients to estimate direct and indirect costs 
associated with each visit from the onset of symptoms 
until TB diagnosis, using a standardised questionnaire.32 
Direct costs included costs for diagnosis (such as costs for 
X-rays), medical costs (as costs for drugs that excluded 
TB drugs), food, transport and other costs that included 
special supplements and vitamins. Indirect costs included 
income reduction, decreased production costs, coping 
costs (including the use of savings or selling of house-
hold assets to cater for sickness) and reduced payment 
for labour. Calculation of patient costs relied on the 
2008 WHO tool.32 We report costs as US Dollars (USD), 
converted from Tanzania shillings using the exchange 
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rate from the Bank of Tanzania of USD/TZS 2167.84 as 
of August 2016.
Definitions
A new patient with TB was defined by bacteriological 
confirmation with sputum smear microscopy and/or 
Xpert MTB/RIF in the absence of prior TB treatment 
during screening.33 A patient with presumptive TB was 
defined by presentation with TB symptoms, including 
coughing for longer than 2 weeks, fever, night sweats 
or unexplained weight loss, and who tested negative on 
sputum smear or Xpert MTB/RIF.33 Diagnostic delay was 
defined according to the framework of WHO and used 
in previous studies34 35 as the interval between the onset 
of any TB-related symptom and the time of TB diagnosis 
of more than 3 weeks. Healthcare provider was defined 
as a person or facility that could provide healthcare, this 
included hospitals, pharmacies and dispensaries, as well 
as traditional healers. Prior medication was defined as the 
use of any prescribed or self-prescribed medication prior 
to TB diagnosis.4 We defined patients as poor if their 
wealth fell in the lowest or second-lowest wealth  quantile. 
The non-poor were defined as persons in the remaining 
middle, fourth and highest wealth quantiles.36
statistical and geographical analysis
We performed descriptive analyses to summarise the data 
and used χ2 or Fisher’s test to assess differences between 
groups in categorical variables. ‘A cut-off point of 300 
USD was used as a threshold for the monthly household 
income as indicated in another similar study.4 Cost distri-
butions were described by their medians and IQRs. Costs 
were further calculated stratifying by gender and poverty 
status. Wealth quantiles were generated following a prin-
cipal component analysis of standard household assets as 
indicated in the Tanzania household survey.26 To stratify 
between the poor and non-poor, we used wealth indica-
tors relating to household characteristics (eg, roofing 
type, cooking fuel and nature of flooring) and ownership 
of assets (eg, radio and mobile phone) to create wealth 
ranking as used in other studies.37 38 Patients in the first 
and second quantiles were considered poor and in the 
remaining quantiles as non-poor. We used the non-para-
metric Kruskal-Wallis test to assess the statistical signifi-
cance of the differences in estimated costs between 
groups. All significance tests were two-sided with a confi-
dence level of 95%. Quantile regression models were 
performed for median costs to examine the association 
Figure 1 Flowchart of the study population. Participants were enrolled until the final target of 100 patients with confirmed and 
100 patients with presumptive TB was reached. 
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of patient factors with the different types of costs. Factors 
considered in these models included male versus female, 
age in years, unskilled and semi-skilled labour, level of 
education and diagnostic delay. Statistical analyses were 
performed using Stata V.14.0 . ( Stata Corporation, 
College Station, TX, USA)
We mapped and visualised the pathways of patients to 
healthcare providers up to a maximum of five visits for the 
current episode of sickness as described elsewhere.3 14 We 
calculated straight lines distances in metres between the 
patient's household and the nearest health facility. The 
resulting distances were imported into Stata for further 
analyses. All geographical analyses were performed using 
ArcGIS (V.10.5, Esri Redlands, CA, USAAll maps were 
obtained from Open Street Maps.
Patient involvement
Patients were not involved in the development, design 
and analysis of this study.
results
Patient characteristics
The study population includes 100 patients with confirmed 
and 100 patients with presumptive TB (table 1). Patients' 
median age was 34 years, with patients with presump-
tive TB being slightly older than the confirmed patients. 
Men slightly predominated (55.5%) and accounted for 
almost two-thirds of the confirmed patients. Compared 
with patients with presumptive TB, confirmed patients 
had a somewhat higher education, were less likely to 
own a house and more likely to use a car transport for 
their first point of care. They more frequently used medi-
cation after the onset of symptoms and prior to seeking 
care at the health facilities (71% vs 44%, p<0.001). The 
proportion of patients with a monthly household income 
of less than USD 300 was 63% in confirmed and 75% in 
presumptive patients (p=0.06).
First point of care and diagnostic delay
Among confirmed patients, 44% first sought care at 
pharmacies after the onset of symptoms, whereas 42% 
of presumptive patients first sought care at hospitals 
(table 1). Fewer than 10% of patients in both groups 
reported visits to traditional healers as the first point of 
care. Confirmed patients frequently indicated more than 
two visits at health facilities (33% vs 9%, p<0.001).
The average time for first seeking healthcare after the 
onset of symptoms was 2 weeks. Overall, 45.5% sought 
care within 1 week after the onset of TB symptoms. For 
30%, the diagnostic was established within 2–3 weeks. 
For about a tenth, there was a diagnostic delay of 6 weeks 
or more. The diagnostic delay differed significantly 
between confirmed and presumptive patients, with 41% 
of confirmed versus 50% of presumptive patients having a 
short delay (of <1 week). Higher proportions of confirmed 
patients had a diagnostic delay of 4–5 and of ≥6 weeks.
Pathways to care
The spatial distribution of healthcare facilities in the 
study area shows pharmacies and dispensaries are distrib-
uted over the whole area (figure 2A). Hospitals are situ-
ated mainly in the urban centres and traditional healers 
predominantly in the peripheral area. Figure 2B,C 
offer examples of pathways to care until TB diagnosis 
in confirmed and presumptive patients. Pathways in 
confirmed patients involved several visits to the health-
care facilities before TB diagnosis. Pathways in presump-
tive patients were more direct with only one or few visits 
to healthcare facilities before TB diagnosis.
The median distance from patients' households to 
healthcare facilities including hospitals, pharmacies, 
dispensaries, and traditional healers was 2338 m (IQR 
1373–4122) for confirmed patients and 2009 m (IQR 
986–2976) for presumptive patients (p=0.25). Among 
confirmed patients, 37% lived within 500 m as did 42% of 
presumptive patients. Eighty-three per cent of confirmed 
patients and 72% of presumptive patients lived within 
1000 m from the nearest hospital. We did not find an 
association of the distance from patients’ household to 
the nearest possible healthcare facility with patient char-
acteristics such as being poor (defined as being in the 
lowest two wealth  quantiles), prior use of medication, 
or having more than two healthcare visits in multivariate 
analysis.
While seeking care at pharmacies was prominent for 
the first visit in confirmed patients and also reported by 
a fifth of the presumptive patients, subsequent visits at 
pharmacies were mentioned much less (figure 3). The 
second visit was characterised by a large proportion  of 
patients seeking healthcare at hospitals in both groups. 
Confirmed patients had more visits to healthcare facili-
ties compared with presumptive patients (none of the 
presumptive patients indicated a fourth and fifth visit).
Costs associated with seeking care
Patients spent a median of 31% (IQR 15.0%–56.3%) 
of their monthly household income for health expen-
ditures for all visits for TB diagnosis. For the first visit, 
confirmed patients had lower median costs than presump-
tive patients (USD 8.3 [IQR 4.6–17.5] vs 13.8 [IQR 
6.0–20.5]), but their costs became comparatively higher 
with increasing number of visits (see online supplemen-
tary table 1).
Overall, indirect costs were considerably higher than 
direct costs, both in confirmed and presumptive patients 
from the onset of symptoms until confirmation/exclu-
sion of TB (table 2). Confirmed patients had higher diag-
nostic costs than presumptive patients (USD 7.0 [IQR 
5.8–9.2] and 5.3 [IQR 1.4–7.0]), higher food costs and 
higher informal payments. Among the indirect costs, 
income reduction was considerably higher for patients 
with confirmed TB than presumptive patients (USD 23.1 
[IQR 6.9–55.4] vs 9.2 [IQR 1.4–25.4]).
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Table 1 Socio-demographic characteristics and diagnostic delay for the patients with confirmed and presumptive 
tuberculosis (TB).
Variable n (%) All n=200 Confirmed n=100 Presumptive n=100 P value
Age in years (median, IQR) 34 (27–41.5) 32.5 (26–39) 34 (29–43) 0.055*
Age groups 0.22
  18–27 years 52 (26) 30 (30) 22 (22)
  28–37 years 75 (37.5) 39 (39) 36 (36)
  >38 years 73 (36.5) 31 (31) 42 (42)
Sex 0.016
  Male 111 (55.5) 64 (64) 47 (47)
  Female 89 (44.5) 36 (36) 53 (53)
Education 0.023
  No education 34 (17) 12 (12) 22 (22)
  Primary education 122 (61) 59 (59) 63 (63)
  Secondary/university 44 (22) 29 (29) 15 (15)
Occupation 0.081
  Unemployed/housewife 59 (29.5) 30 (30) 29 (29)
  Unskilled labour 49 (24.5) 18 (18) 31 (31)
  Semiskilled labour 92 (46) 52 (52) 40 (40)
Household size 0.67 
  <4 93 (46.5) 45 (45) 48 (48)
  ≥4 107 (53.5) 55 (55) 52 (52)
House ownership 0.050
  Rented 135 (67.5) 74 (74) 61 (61)
  Own 65 (32.5) 26 (26) 39 (39)
Household income 0.067
  ≤300 USD per month 138 (69) 63 (63) 75 (75)
  >300 USD per month 62 (31.0) 37 (37) 25 (25)
Wealth quantile 0.54
  Poor households 47 (23.5) 21 (21) 26 (26)
  Second 33 (16.5) 16 (16) 17 (17)
  Middle 41 (20.5) 19 (19) 22 (22)
  Fourth 44 (22) 27 (27) 17 (17)
  Non-poor households 35 (17.5) 17 (17) 18 (18)
Prior medication <0.001
  Yes 115 (57.5) 71 (71) 44 (44)
  No 85 (42.5) 29 (29) 56 (56)
First point of care 0.004
  Hospitals 70 (35) 28 (28) 42 (42)
  Dispensaries 49 (24.5) 19 (19) 30 (30)
  Pharmacies 66 (33) 44 (44) 22 (22)
  Traditional healers 15 (7.5) 9 (9) 6 (6)
HC facility visits <0.001
  ≤2 158 (79) 67 (67) 91 (91)
  >2 42 (21) 33 (33) 9 (9)
Transport used for first point of care <0.001
  Car 70 (35.5) 22 (22) 48 (48)
Continued
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gender, poverty status and costs
Costs for different patient groups differed significantly. 
Overall, the median total direct costs were similar for 
men, USD 24.9 (IQR 17.5–41.9), and women, USD 24.6 
(IQR 16.1–42.4 p=0.66). Indirect costs for men, USD 64.6 
(IQR 31.8–159.1), were significantly higher than those 
for women, at USD 55.6 (IQR 25.1–141.1, p<0.001).
Analyses stratified by sex and poverty status indicate 
that poor men with confirmed TB had lower total direct 
costs compared with poor women (USD 24.4 [IQR 
18.9–47.9] vs 30.0 [IQR 18.7–49.6]) (table 3). For the 
patients with presumptive TB, total direct costs for poor 
men differed slightly from those of poor women (USD 
22.6 [IQR 17.5–29.1] vs 20.5 [IQR 14.3–35.1]). Among 
Variable n (%) All n=200 Confirmed n=100 Presumptive n=100 P value
  On foot 95 (47.5) 65 (65) 30 (30)
  Motorcycle/tricycle 35 (17.5) 13 (13) 22 (22)
Diagnostic delay  0.04 
  0–1 91 (45.5) 41 (41) 50 (50)
  2–3 60 (30) 26 (26) 34 (34)
  4–5 27 (13.5) 19 (19) 8 (8)
  6+ 22 (11) 14 (14) 8 (8)
P values provided by χ2 tests and Fisher’s exact test.
*Wilcoxon-rank sum test.
HC, health care facility; USD, United States Dollar.
Table 1 Continued 
Figure 2 Geographical analyses of healthcare facilities and pathways to care of patients with confirmed and presumptive TB in 
Temeke District, Dar es Salaam, Tanzania. Various types of healthcare facilities as the entry point into the healthcare system until 
final diagnosis at the TB clinic are shown.Panel A: Spatial distribution of healthcare facilities in the study area. Panel B: Possible 
pathways to care of patients with confirmed TB while seeking healthcare. Panel C: Possible pathways to care of patients with 
presumptive TB while seeking healthcare. 
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the non-poor men and women, direct costs differed only 
little  between confirmed and presumptive patients. In 
confirmed patients, diagnostic costs were lower among 
poor men compared with poor women (USD 6.91 [IQR 
4.61–9.22] vs 7.61 [IQR 1.38–10.14]), whereas for the 
presumptive patients, diagnostic costs were the same 
among poor men and women.
Total indirect costs, (table 4) among poor patients with 
confirmed TB were higher in men than women, (USD 
84.4 [IQR 55.3–125] vs 51.7 [IQR 27.6–73.4]), while this 
gender difference was absent in non-poor confirmed 
patients. Among patients with presumptive TB, poor men 
faced higher total indirect costs than poor women (USD 
50.2 [IQR 27.6–83.4]) vs 39.2 [IQR 18.6–116.0]).
Determinants of cost differences
On average, each week of diagnostic delay was associated 
with an increase in median total costs (direct and indirect 
costs) among confirmed patients by 1.44 USD (95% CI: 
0.93,1.96), p<0.001), but no significant association was 
seen in presumptive patients (table 5). Diagnostic delay 
was associated with an increase in total direct costs in 
confirmed patients (USD 0.52 per week, 95% CI: (0.34 to 
0.70), p<0.001), but with a decrease in presumptive 
patients (USD −0.84 per week, 95% CI: (−1.32 to –0.35), 
p=0.001). For total indirect costs, the pattern was similar, 
but neither of the two associations reached statistical 
significance.
Overall, having a university degree was significantly 
associated with higher indirect costs (USD 70.14, 95% CI: 
[9.47 to 130.80], p=0.02). None of the other factors of 
the model were significantly associated with median 
costs. The pattern of positive association between diag-
nostic delay and total costs among confirmed patients 
and negative association among presumptive patients 
was further supported by analyses using linear and 
quadratic terms (figure 4). Furthermore, we conducted 
regression analyses separately for different types of costs 
(see online supplementary tables 2 and 3). Medication 
costs in confirmed patients increased with the number of 
weeks of delay (USD 0.13 per week, 95% CI: [0.06 to 0.19], 
Figure 3 Spine plots showing distribution of healthcare facility visits during the pathway to care (first, second, third and fourth/
fifth visit) in confirmed and presumptive patients. Numbers on the graph indicate absolute frequencies.
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p<0.001), but not in presumptive patients. Transport costs 
were significantly lower among men and women with 
presumptive TB (USD −1.54, 95% CI: [−3.12 to –0.03], 
p<0.05). We further observed an increase in coping costs 
with the length of diagnostic delay in both confirmed and 
presumptive patients (see online supplementary table 
3). Finally, in patients with presumptive TB, costs due to 
decreased production were significantly higher among 
unskilled labourers (USD 8.71, 95% CI: [0.53 to 16.89], 
p=0.03).
DisCussiOn
This study indicates that pathways to care of the patients 
with confirmed TB are more complex compared with 
those of presumptive patients, involving visits at several 
healthcare providers among whom not all have necessary 
diagnostic equipment. A diagnostic delay of 6 weeks or 
more after the onset of symptoms was reported by 10% of 
the patients. Fifty per cent of the patients visited health-
care facilities within 1 week after onset of symptoms. In 
seeking care, patients incur substantial direct and indirect 
costs. The costs of care were higher in confirmed patients 
than in presumptive patients. For half of the confirmed 
patients, direct costs account for more than 30% of the 
monthly household income. Total costs were associated 
with diagnostic delay among confirmed patients only. 
The indirect costs were higher for men than for women 
whereas direct costs did not differ. Among the poor, direct 
costs were higher in women and indirect costs higher in 
men.
Almost half of the patients with confirmed TB began 
their search for care at pharmacies, and patients in both 
groups sought care from more than one healthcare 
provider before a diagnosis. This highlights a diagnostic 
shortfall in some healthcare facilities and poor manage-
ment of patients as documented elsewhere,39 and partially 
explains the diagnostic delay. Compared with findings 
of other studies,19 40 the observed diagnostic delay in 
our study was lower. However, a delay of at least 6 weeks 
observed in 10% of our study population still requires 
attention. Most patients lived near healthcare facilities, 
and only 9% of the patients with confirmed TB and 6% of 
the patients with presumptive TB reported visiting tradi-
tional healers. Living near healthcare facilities might have 
an impact on treatment seeking.41 We investigated the 
impact of geographical distance between household and 
health facility on health-seeking behaviour, but found no 
associations between distance and patient characteristics 
such as being poor, prior use of medication and having 
more than two visits to the healthcare facility. This is 
contrary to some other results that found distance to have 
an impact on patient characteristics such as treatment 
completion and diagnostic delay.35 42 43 Diagnostic delay 
was significantly associated with direct costs, indirect costs 
(borderline significance) and total costs in confirmed 
patients. The most likely explanation for this finding is 
Table 2 Direct and indirect costs (in USD) from the onset of symptoms until confirmation/exclusion of TB among patients with 
confirmed and presumptive TB.
Costs All n=200 Confirmed n=100 Presumptive n=100 P value
Average number of visits (range) 1.2 (1–5) 1.3 (1–5) 1.1 (1–3)
Median, (IQR) Median, (IQR) Median, (IQR)
Direct costs
  Diagnostic costs 7.0 (2.3–8.8) 7.0 (5.8–9.2) 5.3 (1.4–7.0) <0.001
  Medication costs 2.8 (1.4–8.0) 2.8 (1.4–9.2) 2.8 (1.4–7.4) 0.873
  Food costs 2.3 (1.4–4.2) 3.2 (1.8–5.3) 1.8 (1.0–2.5) <0.001
  Transport costs 3.2 (1.8–5.5) 3.2 (1.4–5.5) 3.7 (1.8–6.00) 0.154
  Informal payments 2.3 (1.4–4.2) 2.8 (2.3–7.4) 2.1 (1.0–2.8) <0.001
  Other direct costs 4.6 (2.3–9.7) 4.6 (2.3–9.5) 4.4 (2.3–9.7) 0.567
Subtotal direct costs 24.7 (16.1–42.4) 27.4 (18.7–48.4) 19.8 (13.8–33.9) 0.02
Indirect costs (median, [IQR])
  Coping costs 11.3 (4.6–23.1) 11.5 (4.61–20.98) 9.2 (4.6–27.7) 0.765
  Income reduction 15.7 (3.7–36.9) 23.1 (6.9–55.4) 9.2 (1.4–25.4) 0.001
  Decreased production 9.2 (1.4–23.06) 10.0 (3.2–26.3) 9.2 (0–16.8) 0.137
  Less paid labour 4.61 (0–12.0) 5.07 (0–15.22) 4.61 (0–9.2) 0.467
  Other indirect costs 8.5 (1.8–19.4) 11.8 (1.4–23.1) 6.5 (2.3–13.8) 0.056
Subtotal indirect costs 60.0 (25.1–141.1) 66.9 (35.1–149.9) 46.8 (20.1–115.3) 0.006
Total costs 83.0 (46.4–173.9) 99.2 (64.3–190.0) 67.11 (37.1–161.0) 0.003
P values provided by Wilcoxon rank sum test.
IQR, Interquartile range, TB, tuberculosis; USD, United States Dollar (1 USD=2168 Tanzania shillings, exchange rates as of August 2016).
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that diagnostic delay worsens patients’ morbidity, espe-
cially in patients with confirmed TB, thus increasing costs 
of healthcare.42
Patients in both groups spent a median proportion of 
around 30% of their monthly household income on health 
expenditures for up to five visits. The economic burden 
of direct and particularly indirect costs of seeking TB care 
for patients and their households are high for the margin-
alised population, which is most at risk of acquiring TB. 
These findings are consistent with other studies that show 
patients in low-income and middle-income countries face 
a very high economic burden of seeking TB care13 and 
expenditures for seeking healthcare for TB can cause 
or exacerbate poverty.44 The total costs for patients with 
presumptive TB were lower compared with confirmed 
cases in our study. These results are also consistent with 
those reported in other settings where half of the total 
costs for seeking healthcare are pretreatment costs which 
disproportionately affect poor patients with TB.13
While direct costs were relatively low, they may be 
catastrophic for patients who are semiskilled labourers 
reporting monthly household income of less than 300 
USD. Their situations can further be worsened by employ-
ment in the informal sector that lacks sickness benefits.44 
Patients with confirmed TB encountered higher indirect 
costs compared with presumptive patients, which may be 
due to the prolonged time required for diagnosis leading 
to their substantially higher income reduction as shown 
in our study.
We found higher indirect costs among poor men 
compared with poor women. This was mainly due to 
their more pronounced income reduction and decreased 
production. Although the direct and indirect costs were 
higher for men than for women, the costs of ill health are 
usually more profound for women and their households 
than for men. When women get sick the impact of the 
disease on their children and their families is stronger 
than when men get sick.11 Furthermore, financial burden 
may limit access to care for both confirmed and presump-
tive female TB patients since most of them lack financial 
autonomy. Moreover, their lower status in households 
deprioritises their health.
strengths and limitations of this study
Our study is the first to look at pathways to care and assess 
costs of care before the start of treatment in patients with 
confirmed and presumptive TB in an urban Tanzania 
setting. Studies have focused on pathways and costs of 
care in patients with confirmed TB and ignore the effects 
on presumptive cases. Furthermore, it’s the first study to 
estimate costs by stratifying according to poverty status 
and gender in sub-Saharan Africa. However, this study 
has some limitations. First, recall bias is a concern when 
inquiring about the costs incurred during healthcare 
seeking. This might influence the accuracy of the reported 
costs and pathways to care. However, we attempted to 
limit the recall bias by linking questions about costs with 
memorable events such as the onset of symptoms or first 
care seeking. Our interviews were also conducted by 
well-trained personnel who spent enough time with the 
respondents so as to obtain answers that were as accurate 
as possible. Furthermore, we only addressed pathways and 
costs of care until TB diagnosis to the public healthcare 
facilities. Therefore, we might have left out costs of care 
for the patients who had their final diagnosis at the private 
and faith-based healthcare facilities. Finally, we only esti-
mated the costs for TB diagnosis. However, comorbidities 
may have caused higher costs, but this is equally true for 
confirmed as well as patients with presumptive TB.
COnClusiOns
This study demonstrates the complexity of pathways until 
diagnosis in patients with confirmed TB. It also high-
lights the high financial burden for the period between 
symptom onset and diagnosis for patients with confirmed 
and presumptive TB and points to different direct and 
indirect costs among poor men and women. This under-
scores the need to strengthen the healthcare sector to 
ensure early diagnosis of TB. Ensuring integration of 
Figure 4 Margin plots showing associations between total costs and diagnostic delay in patients with confirmed TB (panel A) 
and patients with presumptive TB (panel B). Associations between median total costs and diagnostic delay were modelled by 
quadratic polynomials. The p values are from Wald test of the linear and quadratic terms of the diagnostic delay (p<0.001 for 
panel A, p=0.08 for panel B). 
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different healthcare providers including private, public 
health practitioners and patients themselves could help 
in reducing the complex pathways during healthcare 
seeking and optimal healthcare utilisation.39 Reducing 
the direct and indirect costs associated with treatment 
seeking is likely to support patients with confirmed and 
presumptive TB in timely accessing healthcare for TB 
diagnosis and treatment. Decreasing or removing user 
fees and further decentralisation of TB care could reduce 
diagnostic delay and lower expenditures. Additionally, 
strengthening of health systems policies including protec-
tion of patients against thesubstantial direct and indirect 
costs, as well as ensuring universal access to healthcare 
must be interpreted into actions for a better TB control.45 
These interventions are central for reaching the ambi-
tious WHO targets of zero deaths, disease and suffering 
due to TB by 2035.46
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